14
Attacking Devastating Diseases Attacking Devastating Diseases With Breakthrough Science With Breakthrough Science Neuroscience Neuroscience Martin Mackay, Ph.D. Martin Mackay, Ph.D. Senior Vice President Senior Vice President Worldwide Research and Technology Worldwide Research and Technology Valid as of November 30, 2006

Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

Attacking Devastating Diseases Attacking Devastating Diseases With Breakthrough Science With Breakthrough Science

NeuroscienceNeuroscienceMartin Mackay, Ph.D.Martin Mackay, Ph.D.Senior Vice PresidentSenior Vice President

Worldwide Research and TechnologyWorldwide Research and Technology

Valid as of November 30, 2006

Page 2: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

Neuroscience VisionNeuroscience Vision

We will Change Society We will Change Society by Lifting the Burden ofby Lifting the Burden of

Neuropsychiatric DiseaseNeuropsychiatric Disease

Valid as of November 30, 2006

Page 3: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

Progress in Our LifetimesProgress in Our Lifetimes

Strategy in BriefStrategy in Brief

AlzheimerAlzheimer’’s Disease s Disease –– Fully Exploit Fully Exploit Scientific BreakthroughsScientific BreakthroughsCognition and ADHD Cognition and ADHD –– Increased Effort Builds Increased Effort Builds Upon Internal DiscoveriesUpon Internal DiscoveriesBipolar Disorder and Schizophrenia Bipolar Disorder and Schizophrenia –– Advance Advance Several Programs Into The ClinicSeveral Programs Into The ClinicDepression and Anxiety Depression and Anxiety –– Leverage New Science Leverage New Science to Discover Novel Targetsto Discover Novel TargetsSleep Quality Sleep Quality –– Mine the Mine the αα22δ δ AdvancesAdvances

Valid as of November 30, 2006

Page 4: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

Phase 1Phase 1

PreclinicalPreclinical

Phase 3Phase 3

Phase 2Phase 2

A Substantial And Broad ProgramA Substantial And Broad Program

Lyrica for FibromyalgiaLyrica for Fibromyalgia

Alpha 2 Delta for GAD; Alpha 2 Delta Alpha 2 Delta for GAD; Alpha 2 Delta for Insomnia; RAGE for ADDMfor Insomnia; RAGE for ADDM

mAb for Pain; mAb for Pain; PGE2/EP4 for OA; PGE2/EP4 for OA; NRI for NeP/FibromyalgiaNRI for NeP/Fibromyalgia

SSRI/5HT1b for DepressionSSRI/5HT1b for Depression

27 Candidates for Schizophrenia, 27 Candidates for Schizophrenia, ADDM, ADHD, Anxiety, ADDM, ADHD, Anxiety, Depression and PainDepression and Pain

2 Candidates for ADDM (A2 Candidates for ADDM (Aββ & RAGE & RAGE mAbmAb))7 Candidates for Schizophrenia, 7 Candidates for Schizophrenia,

Depression & PainDepression & Pain

Valid as of November 30, 2006

Page 5: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

Key ProgramsKey Programs

Lyrica for Fibromyalgia* Lyrica for Fibromyalgia* S,SS,S--Reboxetine for Neuropathic Pain*Reboxetine for Neuropathic Pain*αα22δδ Platform*Platform*AlzheimerAlzheimer’’s Diseases Disease

RN1219 RN1219 -- RinatRinatTTP488/TTP4000 TTP488/TTP4000 -- TransTechTransTech

SchizophreniaSchizophreniaPDEPDE--10 Inhibitor10 Inhibitor

*Indicates First-Time Disclosure By Pfizer Today*Indicates First-Time Disclosure By Pfizer Today

Valid as of November 30, 2006

Page 6: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

LyricaLyricaA Breakthrough for FibromyalgiaA Breakthrough for Fibromyalgia

Clinical FeaturesChronic, Widespread PainDecreased Pain Threshold Several Co-Morbidities (e.g., Sleep, Fatigue, Anxiety)

High Medical Need

Prevalent, Poorly Diagnosed, and Badly Managed ConditionNo Approved Medicines

Clinical FeaturesClinical FeaturesChronic, Widespread PainChronic, Widespread PainDecreased Pain Threshold Decreased Pain Threshold Several CoSeveral Co--Morbidities Morbidities (e.g., Sleep, Fatigue, Anxiety) (e.g., Sleep, Fatigue, Anxiety)

High Medical NeedHigh Medical Need

Prevalent, Poorly Diagnosed, Prevalent, Poorly Diagnosed, and Badly Managed Conditionand Badly Managed ConditionNo Approved MedicinesNo Approved Medicines

Valid as of November 30, 2006

Page 7: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

New Data New Data –– Just ReleasedJust Released

Lyrica (mg/day)

-3.0

-2.5

-2.0

-1.5

-1.0

-0.5

0.0Pl acebo (n=1 29) 1 50 (n=131) 300 (n=1 32) 450 (n=128 )

p=0.0009p=0.0009

Mea

n C

hang

e fr

om B

asel

ine

Mea

n C

hang

e fr

om B

asel

ine

Sustained Efficacy in Fibromyalgia PatientsSustained Efficacy in Fibromyalgia Patients

Valid as of November 30, 2006

Page 8: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

S,SS,S--ReboxetineReboxetineNeuropathic PainNeuropathic Pain

Chronic, NonChronic, Non--Malignant Malignant Pain Where the Central Pain Where the Central Nervous System is Nervous System is MalfunctioningMalfunctioning

S,SS,S--Reboxetine is a Highly Reboxetine is a Highly Selective Norepinephrine Selective Norepinephrine Reuptake Inhibitor (NRI)Reuptake Inhibitor (NRI)

ControlledControlled--Release Release Formulation for Formulation for OnceOnce--Daily AdministrationDaily Administration

Valid as of November 30, 2006

Page 9: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

Pain Relief in Treatment FailuresPain Relief in Treatment Failures

Placebo

S,S-Reboxetine

Placebo

S,S-Reboxetine

44

55

66

77

Wee

kly

Aver

age

Pain

Sco

reW

eekl

y Av

erag

e Pa

in S

core

11 5544332200

Time (Weeks)Time (Weeks)

Valid as of November 30, 2006

Page 10: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

A Thriving A Thriving αα22δδ PortfolioPortfolio

α2δαα22δδ

AnxietyAnxietyAnxiety

SleepSleepSleep

Hot FlashesHot FlashesHot Flashes

PF-293,765

PF-2,393,296

Lyrica

PF-293,765

PF-2,393,296

Lyrica

PD-332,334

Lyrica

PD-332,334

Lyrica

PD-200,390 PD-200,390

PD-299,685PD-299,685

PainPain

NeuroscienceNeuroscience

Women’s HealthWomen’s Health

Neuropathic Pain

Neuropathic Neuropathic PainPain

Valid as of November 30, 2006

Page 11: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

PDPD--332,334 332,334 Impressive Results in AnxietyImpressive Results in Anxiety

13%13%

29%29%26%26%

31%31%

48%48%

38%38%

0%0%

10%10%

20%20%

30%30%

40%40%

50%50%

Res

pond

er R

ates

(%)

Res

pond

er R

ates

(%)

Week 1Week 1 Week 4Week 4

% of Patients Greater Than or % of Patients Greater Than or Equal to 50% Reduction HAMEqual to 50% Reduction HAM--AA

PlaceboPlacebo

PDPD--332,334 250mg BID332,334 250mg BID

XanaxXR 1mg BIDXanaxXR 1mg BID

Valid as of November 30, 2006

Page 12: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

PDPD--200,390 200,390 A Breakthrough for Sleep QualityA Breakthrough for Sleep Quality

Insomnia Impacts 50% Insomnia Impacts 50% of General Populationof General Population

10% of General 10% of General Population Suffer from Population Suffer from Poor Sleep QualityPoor Sleep Quality

Program Covers Program Covers Insomnia and Insomnia and Sleep QualitySleep Quality

Valid as of November 30, 2006

Page 13: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

PDPD--200,390200,390Total Sleep TimeTotal Sleep Time

PlaceboPlacebo PDPD--200,390200,390 ZolpidemZolpidem

Mea

n To

tal S

leep

Tim

e (m

in)

Mea

n To

tal S

leep

Tim

e (m

in)

340340

360360

380380

400400

420420

440440

Placebo

PD-200,390

Zolpidem

PlaceboPlacebo

PDPD--200,390200,390

ZolpidemZolpidem

Valid as of November 30, 2006

Page 14: Attacking Devastating Diseases With Breakthr ough Science … · 2020. 5. 7. · Attacking Devastating Diseases With Breakthr ough Science Neuroscience Martin Mackay, Ph.D. Senior

PDPD--200,390200,390Number of AwakeningsNumber of Awakenings

PlaceboPlacebo

Mea

n Nu

mbe

r of

Aw

aken

ings

Mea

n Nu

mbe

r of

Aw

aken

ings

00

22

44

66

88

1010

PDPD--200,390200,390 ZolpidemZolpidem

Placebo

PD-200,390

Zolpidem

PlaceboPlacebo

PDPD--200,390200,390

ZolpidemZolpidem

Valid as of November 30, 2006